MOR209/ES414 is a humanized, bispecific ADAPTIR™ molecule that binds to prostate-specific membrane antigen (PSMA) and CD3. PSMA expression is upregulated in prostate cancer and is highest in advanced, metastatic castration-resistant prostate cancer (mCRPC).
The MOR209/ES414 mechanism of action is to redirect T cells to kill PSMA-expressing tumor cells.
In addition to potential utility as a monotherapy, the MOR209/ES414 mechanism of action may provide a complementary approach to mCRPC treatment when used in combination with other therapies.
In 2014, we entered into a co-development license agreement with MorphoSys to develop MOR209/ES414. Aptevo Therapeutics retains North American commercial rights to the candidate.